Product Spotlight: 3D-PHAD

Posted on November 12, 2019


Adobe Stock 265265863

Comparable to bacterial MPLA and other synthetic MPLA analogs at eliciting an immune response in a liposomal adjuvant system, 3D-PHAD is less pyrogenic than its bacterial-derived mimic. Extensive preclinical testing with 3D-PHAD demonstrated equivalency to PHAD, and human trials are scheduled to launch. The highly pure MPLA analog, 3D-PHAD, provides a homogeneous synthetic equivalent for the 3-deacylated MPLA derived from bacterial LPS. This product is protected under Pat No. 9,241,988.

Adjuvant Formulations

Is your immunotherapy or vaccine program spending valuable time and resources on adjuvant formulation development? Here at Avanti, we have nearly 100 years of combined experience formulating lipids. This experience allows us to support all of your adjuvant formulation development activities.

We offer formulation services for both pre-clinical and clinical development using our own cGMP manufactured lipids. When you order batches, they can be scaled from a few milliliters to over 100 liters to accommodate your stage of clinical development. We work closely with your packaging group through every step of the process, to make sure we provide material suitable for aseptic fill and finish in your final dosage form for clinical trial.

Whenever you’re ready for commercialization, Avanti can work in partnership with you CMO to provide a seamless transfer of the formulation for scale-up and manufacturing.

Licensing Opportunities

Vaccine adjuvants using heterogeneous monophosphoryl Lipid A (MPL) derived from Salmonella minnesota R595 have proven to be safe and effective at inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines. With the introduction of Synthetic MPL derivatives and adjuvant systems, Avanti revolutionized immunotherapy and vaccine development.

Now, we manufacture multiple synthetic analogs of MPL containing a singular molecular species that are as effective and safe at inducing an immune response as their natural product predecessor. PHAD, 3D-PHAD, and 3D(6A)-PHAD are manufactured according to cGMP guidelines and are available in bulk quantities for your clinical trials. Licensing opportunities are available for your field of use—contact adjuvant@avantilipids.com for more information. Interested in learning more about our products? Visit our website today.